As rumors swirl, Actelion chair says 'no sale'

Actelion reiterated it wants to stay independent despite intense takeover speculation, its top managers told the Financial Times. "The board and management are confident about the future prospects of the company as an independent entity and we're not considering a sale," Chairman Robert Cawthorn told the paper. Report

Suggested Articles

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

A new NEJM study found taking hydroxychloroquine after COVID-19 exposure doesn't reduce the risk of an infection. But questions remain.